Navigation Links
Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day
Date:3/4/2009

ALISO VIEJO, Calif., March 4 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has rescheduled the release of its financial results for the fourth quarter and year-ended December 31, 2008 to Wednesday, March 11th in order to complete its year end audit and to more closely coincide with the filing of its Form 10-K for the year ended December 31, 2008.

    Date: Wednesday, March 11, 2009

    Start Time: 5:00 pm EDT

    Call-in Number: 1-800-762-8779
                    (International) 480-248-5081

    Conference ID Number: 3992520

    Webcast: www.clarientinc.com/investor

    Web Replay: For those unable to participate during the live broadcast,
    the webcast replay will be archived at www.clarientinc.com/investor
    shortly after the call and will be available for one year.

    Speakers: Ron Andrews, Vice Chairman and CEO; Dr. Mike Pellini, President
    and COO; Ray Land, CFO

    Format: Discussion of fourth quarter and year-end 2008 financial results
    followed by Q&A

About Clarient

Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

About Safeguard Scientifics

Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com

    CONTACT:

    Allen & Caron Inc.
    Matt Clawson
    949.474.4300
    matt@allencaron.com


'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Clarient Renews and Expands Mezzanine Credit Facility With Safeguard
2. Clarient Partners With Joint Venture Hospital Laboratories to Offer Pathologists Wide Array of Cancer Assays
3. Clarient Reports First Quarter 2008
4. Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
5. Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference
6. Clarient Named to Deloittes 2007 Orange County Technology Fast 50 for Third Consecutive Year
7. Clarient Generates 52% Revenue Increase in Third Quarter 2007
8. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
9. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
10. Clarient to Present at the UBS 2007 Global Life Sciences Conference
11. Cell Therapeutics Reschedules Special Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... , ... Psoriasis: Targets and Therapy has published ... author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy throws ... onset and the severity of psoriasis, and negatively influences the response to systemic ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... individuals’ genetic characteristics and the physical and behavioral worlds in which they ... In personalized medicine, diagnosing an individual’s disease depends on accurately assessing his ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of the ... and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day outside ... of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in high ... Co., the leading provider of secure mobile remote access solution for Japan enterprises. ... CACHATTO remote access solution. Splashtop for CACHATTO will be available as an ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices to ... this approach has proven transformative, both for people who hear voices and for the ... used around the world, but it still lags in the United States. , Now, ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/27/2016)... The healthcare sector is large ... all falling under its umbrella.  A rather overlooked sector ... talked about, these healthcare companies are still trying to ... is by far the largest consumer of the healthcare ... ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. (OTCQB: KGNX), ...
Breaking Medicine Technology: